DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ANLON HEALTHCARE LIMITED (AHCL) share price today?

ANLON HEALTHCARE LIMITED (AHCL) is trading at ₹14.73 on the NSE, down 2.96% on the day. Source: DocStoX.

What is the PE ratio of ANLON HEALTHCARE LIMITED?

ANLON HEALTHCARE LIMITED has a price-to-earnings (PE) ratio of 28.9 in the Healthcare sector.

What is the market capitalisation of ANLON HEALTHCARE LIMITED?

ANLON HEALTHCARE LIMITED has a market capitalisation of approximately ₹793 crore.

ANLON HEALTHCARE LIMITED

AHCL·NSE·Healthcare

₹14.73▼ -0.45 (-2.96%)

Healthcare · Pharmaceuticals

High-quality returns — 26% on equity

Day₹14.70

₹15.18

52W₹9

₹1733%

Open

₹15.15

High

₹15.18

Low

₹14.70

Prev Close

₹15.18

Volume

29.92L

VWAP

₹14.84

Snapshot

Key fundamentals

Market Cap

₹793 Cr

P/E Ratio

28.88Fair

P/B Ratio

3.56

EPS

₹0.51

Book Value

₹4.33

ROE

25.51%Strong

ROCE

25.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.22Low

Face Value

₹2.00

52W High

₹172.75

52W Low

₹9.08

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹8

▼ 47.2%downside

Trading at ₹15 — 47% above our estimate

BearFair valueBull

₹7₹8₹9

/100

Business quality — Solid

Growth 2Profitability 93Efficiency 43Valuation 71

Plain English

Our view

High-quality returns — 26% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 3/9)

Strengths

Low debt relative to equity
Strong returns on equity (26%)
Capital is working hard (ROCE 25%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

26% ROE fading to 12% over ~10 yrs, on ₹4 book

₹8

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹7

Analyst target

No analyst coverage

—

Blended fair value₹8

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (26%)
Capital is working hard (ROCE 25%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

28.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

25.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.22Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹793 Cr

P/B

3.56

EPS

₹0.51

Div Yield

—

What changed

Recent changes

Domestic institutions+0.1% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 28.9×

Growth

Strong

+15% rev CAGR

Profitability

Excellent

25.5% ROE

Financial health

Rock solid

D/E 0.22

Momentum

N/A

No technicals

Today

Trading activity

Delivery %51.2%

Turnover₹444.02L Cr

Trades4,381

VWAP₹14.84

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.0%

+60.8%

10Y

—

Profit

+69.3%

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is expected to give good quarter
Company has delivered good profit growth of 36.4% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has high debtors of 215 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions added 0.11 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

53%

Promoter

Promoters

52.7%0.00

Public

42.4%-0.20

FII / FPI

0.3%+0.09

DII

4.6%+0.11

Total shareholders

12,484+1,072 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter52.68%

FII0.32%

DII4.60%

Public42.40%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]